目的:我们的目标是在专门的妇女和儿童医院为血细胞分析建立适当的审查标准。此外,CellaVisionDI-60被开发为自动数字细胞形态分析仪之一,我们评估了在某些审查标准下是否显示出最有效。
方法:共检测了2890份血液样本,以优化先前建立的SysmexXE-2100对妇女和儿童的审查标准。总共623个样品用于验证标准。
结果:基于初始审查标准的显微镜审查率为51.0%。优化后,降低至17.3%,假阴性率为3.85%。当样品触发血小板或红细胞相关规则时,手动审查结果与CellaVisionDI-60预分类之间的一致性>80%。异常的敏感性(未成熟粒细胞,有核红细胞)的重新分类为90%至100%,假阴性率<5%。然而,当触发\"Blass/AbnLympho?\"和\"非典型Lympho?\"标志时,需要进行直接显微镜检查。
结论:妇女和儿童需要专门的审查标准。自动形态识别系统可能有助于改善审查标准。
OBJECTIVE: We aimed to establish appropriate
review criteria for blood cell analysis in a specialized women\'s and children\'s hospital. Also, the CellaVision DI-60, was developed as one of the automated digital cell morphology analyzer, we evaluated if it was shown to be most effective under the certain review criteria.
METHODS: A total of 2890 blood samples were detected to optimize the previously established review criteria for women and children with the Sysmex XE-2100. A total of 623 samples were used to validate the criteria.
RESULTS: The microscopic-
review rate based on the initial
review criteria was 51.0%. After optimization, it was reduced to 17.3% and the false-negative rate was 3.85%. There was > 80% consistency between manual review results and CellaVision DI-60 preclassification when samples triggered the platelet- or red cell-related rules. The sensitivity for abnormalities (immature granulocytes, nucleated red blood cells) of reclassification was 90% to 100% and the false-negative rate was < 5%. However, direct microscopic
review was required when the \"Blasts/AbnLympho?\" and \"Atypical Lympho?\" flags were triggered.
CONCLUSIONS: Specialized
review criteria are needed for women and children. An automated morphology identification system might help to improve the
review criteria.